Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$98.82 USD

98.82
666,765

+1.62 (1.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Ambrx Biopharma Inc. (AMAM) and HealthEquity (HQY) have performed compared to their sector so far this year.

Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test

by Zacks Equity Research

Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.

Here's Why You Should Add HealthEquity (HQY) to Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

How to Find Strong Buy Medical Stocks Using the Zacks Rank

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Zacks Industry Outlook Highlights Elevance Health, Cencora and HealthEquity

by Zacks Equity Research

Elevance Health, Cencora and HealthEquity have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy Amid Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and HQY are set to gain the most. However, staffing shortages continue to disrupt the growth trend.

Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how HCA Healthcare (HCA) and HealthEquity (HQY) have performed compared to their sector so far this year.

HealthEquity, Inc. (HQY) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

HealthEquity (HQY) is a Top-Ranked Growth Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Align (ALGN) Ailed by Macroeconomic Issues & Currency Headwind

by Zacks Equity Research

Foreign exchange continues to be a major headwind for Align (ALGN) due to a considerable percentage of its revenues coming from outside the United States.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED), backed by the NuVasive merger and its prominence in the musculoskeletal field.

Myriad's (MYGN) New Acquisition to Boost Precision Oncology Arm

by Zacks Equity Research

Myriad Genetics (MYGN) is set to acquire certain assets of IPG, including Precise Liquid, which is expected to be launched later this year.

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.

Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study

by Zacks Equity Research

Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.

Penumbra (PEN) Rides on Vascular Arm Strength Amid FX Woes

by Zacks Equity Research

Penumbra's (PEN) Vascular business is demonstrating strong growth, banking on a rapid increase in sales of vascular thrombectomy products in the United States.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.

ELV or HQY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. HQY: Which Stock Is the Better Value Option?

Abbott's (ABT) Innovations Aid, Macroeconomic Issues Stay

by Zacks Equity Research

Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher (TMO) due to its series of new product launches and promising growth strategy.

Here's Why Investors Should Retain Bruker (BRKR) Stock Now

by Zacks Equity Research

Investors are optimistic about Bruker (BRKR) on solid prospects of BSI Nano group and raised guidance.

IDEXX (IDXX) Enhances Fecal Dx Antigen Testing Platform

by Zacks Equity Research

IDEXX's (IDXX) Fecal Dx antigen testing detects the most prevalent and clinically relevant intestinal parasites in dogs and cats.

Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics

by Zacks Equity Research

Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors remain optimistic about Align Technology (ALGN) due to the progress in the Invisalign portfolio and highly favorable solvency.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.